ArticleArchives of disease in childhood. Fetal and neonatal edition2007
Conservative treatment for patent ductus arteriosus in the preterm.
Article in Archives of disease in childhood. Fetal and neonatal edition, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Patent ductus arteriosus in preterm neonates.Indian journal of pediatrics · 2008Guideline
- A randomized trial of intravenous acetaminophen versus indomethacin for treatment of hemodynamically significant PDAs in VLBW infants.Journal of perinatology : official journal of the California Perinatal Association · 2021Trial
- Trial
- Serial echocardiography in very preterm infants: a pilot randomized trial.Acta paediatrica (Oslo, Norway : 1992) · 2013Trial
- Effectiveness and safety of rectal dexibuprofen versus oral ibuprofen for closure of patent ductus arteriosus in preterm infants with gestational age<34 weeks: A pilot study.International journal of immunopathology and pharmacologyTrial
- Case Report: Comprehensive management of bedside ligation of patent ductus arteriosus in an extremely low birth weight infant.Frontiers in cardiovascular medicine · 2026Article
- Should we "eliminate" PDA shunt in preterm infants? A narrative review.Frontiers in pediatrics · 2024Review
- Transcatheter closure of patent ductus arteriosus in preterm infants: results from a single-center cohort.Frontiers in pediatrics · 2023Article
- Echocardiographic assessment of intimal thickness growth of patent ductus arteriosus in neonates and analysis of influencing factors.The international journal of cardiovascular imaging · 2022Article
- Oral Versus Intravenous Medications for Treatment of Patent Ductus Arteriosus in Preterm Neonates: A Cost-Saving Initiative.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2021Article
- Conservative Treatment Without Any Intervention Compared With Other Therapeutic Strategies for Symptomatic Patent Ductus Arteriosus in Extremely Preterm Infants: A Nationwide Cohort Study in Korea.Frontiers in pediatrics · 2021Article
- Drug exposure for PDA closure in France: a prospective, cohort-based, analysis.European journal of clinical pharmacology · 2020Observational
- Patent Ductus Arteriosus of the Preterm Infant.Pediatrics · 2020Review
- Effect of Nonintervention vs Oral Ibuprofen in Patent Ductus Arteriosus in Preterm Infants: A Randomized Clinical Trial.JAMA pediatrics · 2020Article
- Conservative Non-intervention Approach for Hemodynamically Significant Patent Ductus Arteriosus in Extremely Preterm Infants.Frontiers in pediatrics · 2020Review
- Transcatheter Closure of Patent Ductus Arteriosus in Premature Infants With Very Low Birth Weight.Frontiers in pediatrics · 2020Article
- Transcatheter Closure of Patent Ductus Arteriosus in Infants With Weight Under 1,500 Grams.Frontiers in pediatrics · 2020Review
- Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol.Frontiers in pediatrics · 2020Article
- Patent Ductus Arteriosus and the Effects of Its Late Closure in Preterm Infants with Severe Bronchopulmonary Dysplasia.Neonatology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA patent ductus arteriosus (PDA) is common among preterms, and prophylactic medical treatment has been advocated as the first-line approach. Conservative treatment may result in similar outcome, but without exposure to the harmful side effects of medication. A retrospective analysis revealed a ductal closure rate of 94% after conservative treatment with adjustment of ventilation (lowering the inspiratory time and increasing positive end expiratory pressure) and fluid restriction.
objectiveTo study prospectively over one year the rate of PDA closure, and morbidity and mortality following conservative treatment.
methodProspective study (1 January 2005 - 31 December 2005) including 30 newborns <or=30 weeks' gestation, all of whom were being ventilated and required surfactant. Echocardiography was performed 48-72 h after birth. Clinically important PDA was conservatively treated as described above. The percentage of children with PDA, ductal ligation and major complications was determined.
resultsTen neonates (33%) developed a clinical important PDA. Following conservative treatment the duct closed in all neonates (100%), and none required ductal ligation or medical treatment. The rates of major complications were no higher than those reported by the Vermont Oxford Network and in the literature.
conclusionThe managed care plan resulted in an overall ductal closure rate of 100%. These results suggest that conservative treatment of PDA is a worthy alternative to prophylactic medical treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.